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ABSTRACT
In this report we investigate the interaction of the natural compounds asiatic acid (AA),
asiaticoside (AS), umbelliferone (UM), and betulinic acid (BA) with the amyloid-β (Aβ)
peptide, the aggregation of which is implicated to be the major pathogenic event in
Alzheimer's Disease (AD). Screening of compounds for ability to affect Aβ aggregation
was performed via ThT fluorescence. Only BA showed consistent deviation from
controls, causing virtually instantaneous formation of large amounts of fibrils in a
concentration-dependent fashion. Turbidity assays ensured the aggregation monitored via
ThT was not experimental aberration. Kinetics utilizing ThT and turbidity indicated that
BA causes immediate exponential aggregation before leveling out within 15 min. SEC
demonstrated the decrease in monomer caused by BA within 24 h and indicated that BA
led to a decrease in oligomeric species. Sedimentation assays confirmed that large
amounts of fibrils were formed in 24 h. Circular dichroism (CD) showed that BA caused
instantaneous conversion of Aβ monomer from random coil to β-sheet, and that the
maximal difference in secondary structure from controls was seen at 24 h. Immunoblots
confirmed 24 h fibril formation, and also indicated that BA prevented the formation of
oligomeric species found in control samples. Fluorescence anisotropy confirmed that BA
binds to Aβ with a KDapp of 11.02 ± 2.01 µM. We conclude that AA, AS, and UM do not
directly affect Aβ aggregation, while BA promotes rapid Aβ fibrilization at the expense
of soluble oligomeric species. Because oligomers are the most neurotoxic form of Aβ,
this suggests that BA should be further investigated as a potential therapeutic for AD.
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Introduction
Alzheimer's disease and amyloid-β
Alzheimer's disease (AD) is a progressive, neurodegenerative disorder, and is the
most common among all neurodegenerative diseases. It is characterized by such
symptoms as acute memory loss and cognitive decline. These symptoms are caused by
the deposition of amyloid-β (Aβ) peptide in the brain, forming what are known as senile
plaques, and causing neuronal death, synaptic dysfunction, and loss of brain mass1. These
proteinacious aggregates of Aβ are thought to be the main pathogenic species responsible
for the neuronal loss and toxicity in AD brains. The generation of this hypothesis was
driven largely by the recognition that the gene encoding Aβ is localized on chromosome
21 and that individuals with Down Syndrome – Trisomy 21 – invariably develop AD
pathology2,3. The hypothesis was further strengthened when several familial forms of AD
were traced to mutations in the gene encoding amyloid precursor protein (APP)4. APP is
a membrane-bound protein that is sequentially cleaved by two membrane-bound
proteases (β- and γ-secretase, respectively) extracellularly to generate Aβ5. This process
is not inherently pathogenic, but changes in the cleavage cascade as a result of aging or
mutations lead to the aggregation of Aβ. In particular, mutations in the presenilin genes
(PS1 and PS2) have been shown to increase Aβ aggregation by altering the γ-secretase
mediated cleavage to produce a residue of 42 amino acids (Aβ42), rather than the usual
40 (Aβ40)5,6. Aβ42 has a higher tendency for self aggregation and is the more neurotoxic
of the two forms of Aβ7.
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Aβ aggregation and oligomer toxicity
The process of Aβ aggregation begins when monomeric Aβ spontaneously converts
from random coil to β sheet secondary structure. This conversion allows multiple
monomers to come together to form cross β sheet structures. Individual molecules of Aβ
display a β strand, turn, β strand motif, and adjacent molecules of Aβ associate via
intermolecular interaction of the R groups between the N-terminal β strand of one
molecule and the C-terminal β strand of the other8. In a process analogous to crystal
growth, these small, oligomeric clumps of Aβ serve as nuclei for the recruitment of other
Aβ monomers. This leads to a logarithmic growth phase, in which monomeric and
oligomeric species go on to form insoluble fibrils, which in turn deposit in the brain as
senile plaques. Much early research focused on the insoluble fibers and senile plaques as
the pathogenic species of AD3. However, more recent investigations suggest that the
soluble, intermediate oligomers are the primary neurotoxic agents responsible for the
symptoms of AD9,10. These oligomers exist in equilibrium with the large plaque deposits,
which serve as reservoirs of inactive protein3. Microinjection of isolated oligomers in
mice caused inhibition of long term potentiation (LTP), which is thought to be the
molecular mechanism of memory formation, showing that oligomers exhibited toxicity
even in the absence of monomers and insoluble fibrils11. Indeed, the level of of cognitive
decline and the severity of AD symptoms correlates poorly with the level of insoluble
plaque found in the brain12. In addition, neuroinflammation has been shown to play a key
role in the pathology of AD13,41. This inflammation, mediated largely by microglial cells
– the immune cells of the brain – has been shown to be triggered by the presence of
oligomeric Aβ species, lending further credence to the hypothesis that oligomers are the
primary causative agents of AD14.
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Aβ aggregation occurs via multiple pathways
Although the obligatory “on-pathway” in which monomers proceed continuously
toward fibril formation is certainly a component of the AD disease cascade, recent
research has indicated that Aβ monomer can follow multiple pathways of aggregation,
some of which result in kinetically stable oligomers that fail to proceed to insoluble
fibrils. Hypothesizing that endogenous interfaces, such as those formed by lipid rafts,
influenced the Aβ aggregation pathway, Rangachari and colleagues showed that Aβ
incubated in the presence of sodium dodecyl sulfate (SDS) micelles formed stable dimers
and trimers, while removal of SDS caused these species to shift to unstable, higher
molecular weight oligomers15. Another study found that the presence of non-esterified
fatty acids (NEFAs) near to and above their critical micelle concentration (CMC) caused
the formation of 12-18mers and 4-5mers, respectively, which remained kinetically
trapped in an “off-pathway” as oligomers as long as NEFAs remained in the solution16.
Removal of fatty acids allowed the oligomeric species to go on to form fibrils. However,
even in the presence of NEFAs, an equilibrium exists between monomers, oligomers, and
fibrils, suggesting that the on-pathway and off-pathway may occur simultaneously. It is
possible that shifting this equilibrium in vivo could cause a decrease in the amount of
highly toxic oligomeric species in favor of monomers or fibrillar aggregates.

AD drug development
Development or discovery of molecules that inhibit the aggregation of Aβ has been a
major pursuit of AD research. A number of small molecule inhibitors, including some
natural products, are reported to disrupt Aβ aggregation in vitro and reduce toxicity.
Perhaps the most well known of these molecules is curcumin, a component of
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turmeric17,18. These molecules are thought to destabilize the Aβ fibrils and/or to
significantly reduce the rate of aggregation, but the precise mechanism of inhibition is not
yet clearly understood. Developing Aβ aggregation inhibitors poses several challenges: a)
it is extremely difficult to control of the stage of inhibition during the aggregation
process, and b) inhibition of fibril formation may result in an increase in the
concentrations of the intermediate oligomers along the aggregation pathway, which may
prove to be more detrimental, as smaller soluble oligomers are known to more toxic than
fibrils. Therefore, an ideal way of developing therapeutically viable aggregation
inhibitors would be to trap Aβ at the monomeric level, since monomers are not toxic.
However, it is difficult to design molecules against intrinsically disordered, monomeric
Aβ due to its high conformational flexibility and lack of structurally well-defined
recognition motifs.
Here, we report the interaction of various natural products with Aβ42 peptide and
their effect on the latter’s aggregation process. Many natural products derived from plants
have unique pharmacological properties that can be beneficial in the drug development
process. Ancient forms of therapy, such as the ‘Ayurvedic’ type practiced in India, have
extensively used plant products in the form of herbal concoctions for the treatment of
numerous disorders, including those of the CNS. In this work, we report on the
interactions of the natural compounds asiatic acid (AA), asiaticoside (AS), umbelliferone
(UM), and betulinic acid (BA).
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Asiatic acid and asiaticoside
C. asiatica has been traditionally used in Ayurvedic medicine to treat cognitive
impairment and decline in a concoction comprising C. asiatica and three other herbs to
be taken with milk19. The remedy is said to improve memory, prevent dementia, and fend
off the negative effects of aging. It may also have anti-inflammatory effects.
In fact, C. asiatica has been investigated in several studies related to cognitive
impairment or decline. Haleagrahara and Ponnusamy investigated the neuroprotective
effect of an extract of C. asiatica on reactive oxygen species in rats that had been induced
to have Parkinson's disease20. As in AD, the pathology of Parkinson's disease involves the
creation of free radicals and the oxidative damage done by these radicals on the nerve
tissues. In rats who were exposed to a compound chosen to induce oxidative damage and
C. asiatica extract, levels of lipid hydroperoxides and protein-carbonyl content decreased
while levels of total antioxidants and antioxidant enzyme levels increased, suggesting C.
asiatica extract is capable of protecting the brain from free-radical induced damage. A
study by Tiwari et al. investigated the effect of oral administration of C. asiatica extract
on elderly patients in a hospital to determine its effect on mild cognitive impairment
(MCI)21. After treatment, the participants exhibited an increase in mini mental status
examination (MMSE) scores, a decrease in mean diastolic blood pressure, an increase in
appetite, an improvement in their sense of well being, a decrease in insomnia, and a
decrease in sensations of numbness and burning, perhaps due to anti-inflammatory effects
of C. asiatica extract.
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Figure 1. Amino acid sequence of Aβ42 and Aβ42 mutants; structures of compounds
used in this study.

Patil et al. investigated the effect of asiatic acid, a component of the C. asiatica
extract, along with withanolide A, another plant extract, on multiple targets associated
with APP processing and the clearance of Aβ22. It was found that asiatic acid both
upregulated the activity of the ADAM10 enzyme, which is involved in nonamyloidogenic processing of APP, and downregulated the activity of BACE1, a ratelimiting enzyme involved in the production of Aβ from APP. Asiatic acid was also
investigated by Mook-Jung et al. for its protective effects against Aβ neurotoxicity23. The
researchers used lab-grown cells and applied asiatic acid and two other asiaticoside
derivatives to separate cell cultures. All three compounds were found to reduce cell death
induced by hydrogen peroxide and to lower concentrations of free radicals within the
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cells, with asiatic acid having the strongest effect. In addition, neither asiatic acid nor the
other two compounds showed any toxicity or reduction in function of hippocampal cells.
Another related study investigated the effect of eight semi-synthetic asiatic acid
derivatives for their neuroprotective effect24. This study found asiatic acid to be the most
effective protector against neurotoxicity, demonstrating 97% protection against direct Aβ
toxicity when Aβ was added to a culture of cells. In addition, a study by Boopathy et al.
investigated asiatic acid's effect as an acetylcholinesterase inhibitor25. Elevated
acetylcholinesterase activity is a characteristic feature of AD. Asiatic acid was applied to
hippocampal cell lines, and the cells were then assayed for acetylcholinesterase activity
and for any potentially toxic effect of asiatic acid. Asiatic acid was found to be a very
effective inhibitor of acetylcholinesterase while exhibiting no toxic effects on the
hippocampal cells.
While all of these lines of research directly relate to AD and Aβ toxicity, we were
unable to locate any studies directly investigating the effect of asiatic acid upon Aβ
aggregation. Because of its clear potential to reduce Aβ toxicity, we have decided to
investigate it herein, along with asiaticoside, a closely related compound also found in
extracts of C. asiatica. We observed, however, that in spite of the established
neuroprotective effect of C. asiatica extract and its derivatives, neither asiatic acid nor
asiaticoside exhibited significant fibril inhibition in vitro.

Umbelliferone
Coumarin is a chemical family within the benzopyrene class. Among the coumarins is
the natural product umbelliferone, which is a component of various Ayurvedic remedies
for cognitive impairment44. It is hydrophobic, small, and should therefore be able to
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penetrate the blood-brain barrier. Because of these factors, we included umbelliferone
among our list of compounds to be tested.

Betulinic acid
BA is another natural product and has been used therapeutically both in Ayurveda
and modern medicine. BA is a lupane-type triterpiniod (Figure 1) and a major component
in many different plants including Bacopa monnieria, also known as ‘Bhrami,’ which
grows in south Asia26. Extracts of Bracopa monniera are used in Ayurvedic medicines
for the treatment of CNS disorders and mental function27. They are also thought to
improve higher order cognitive processes that are critically dependent on the input of
information from our environment such as learning and memory28. In addition, the bark
of the white birch, Betula alba, which contains BA, has been extensively used by native
Americans to treat intestinal disorders. Furthermore, BA has also shown great promise as
a potential therapeutic for a variety of cancer types, including neuroectodermal tumors,
and is currently in Phase II clinical trials for the treatment of dysplastic nevi with
moderate to severe dysplasia. Critically, the hydrophobic nature and small size of BA
should enable it to cross the blood-brain barrier, which makes it a compound suitable for
the treatment of CNS disorders26.
Therefore, in this report, we investigate whether BA can interact with Aβ42 in vitro.
We observed that BA binds to Aβ42 and augments its rate of fibril formation in a
concentration-dependant manner. In addition, this augmentation appears to occur in such
a way as to bypass neurotoxic, soluble intermediates along the fibril aggregation
pathway.
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Materials and Methods
Materials
Aβ42 was synthesized at the Peptide Synthesis Facility at the Mayo Clinic
(Rochester, MN) using routine Fmoc chemistry. MALDI-ToF mass spectrometry
revealed > 90% purity of both peptides. SDS, bovine serum albumin, asiatic acid,
asiaticoside, umbelliferone, scopoletin, betulinic acid, and thioflavin T were procured
from Sigma (St. Louis, MO). All other chemicals were obtained from VWR Inc.

Preparation of Aβ42 monomers
Lyophilized stocks of synthetic Aβ42 were stored at - 20 °C, desiccated. Prior to the
experiments, any pre-formed aggregates that may have been present were removed via
size exclusion chromatography (SEC) as previously reported16. Briefly, 1-1.5 mg of the
peptide were dissolved in 0.5 ml of 30 mM NaOH, and allowed to stand at room
temperature for 15 min before loading onto a Superdex-75 HR 10/30 size exclusion
column (SEC) (GE Life Sciences) attached to an AKTA FPLC system (GE Healthcare,
Buckinghamshire). The column was pre-equilibrated in 20 mM Tris-HCl (pH 8.0) at 25
°C and was run at a flow rate of 0.5 mL/min. One minute fractions were collected.
Concentrations of the purified fractions were estimated by UV-Vis spectroscopy on a
Cary 50 spectrophotometer (Varian Inc) using a molar extinction coefficient (ε) of 1490
cm-1 M-1 (www.expasy.org), corresponding to the single tyrosine residue within Ab42.
Peptide integrity after SEC was again confirmed by MALDI-TOF mass spectrometry,
which yielded a single peak corresponding to a monoisotopic molecular mass of 4516.31
Da in a good agreement with the calculated mass of 4514.13 Da. A similar purification
scheme was also adopted for mutant Aβ42 F19W. Monomeric Aβ42 fractions were
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stored at 4 °C and were used within 3 to 4 days of purification in all experiments to avoid
the presence of pre-formed aggregates in our reactions.

Aβ42 oligomer generation
Aβ42 12-18mers were generated by following the method reported previously16.
Briefly, 50 µM Aβ42 was incubated with 5 mM lauric acid at 37 °C for 48 h. The sample
was then fractionated using a Superdex-75 SEC column and the fractions 17 and 18 were
collected for further use.

Aβ aggregation reactions
Unless otherwise noted, reactions and measurements were done at room temperature,
and samples were stored at 37 °C. Reactions were initiated in 0.5 mL siliconized
eppendorf tubes by incubating freshly purified Aβ42 monomer in appropriate conditions
in buffer without agitation. Aggregation parameters were obtained by monitoring the
reaction with thioflavin T (ThT) fluorescence and fitting fluorescence data points to the
sigmoidal curve in eq. 1 using Origin 7.0. In this equation t is time, a and b are fixed
parameters, and t0.5 is the time to reach half-maximal ThT fluorescence. Lag times were

equal to t0.5 – 2b for each curve.

Fluorescence spectroscopy
ThT fluorescence (F) was monitored in a 1 cm quartz microcuvette with a Cary
Eclipse spectrometer (Varian Inc) after 15-fold dilution of Aβ42 samples into 5 mM Tris-
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HCl (pH 8.0) containing 10 µM ThT. Continuous measurements of F were taken for 1min
with the excitation and emission wavelengths fixed at 450 and 482 nm respectively and
both slits set at 10 nm. The fluorescence blanks were subtracted from the respective data
and the average F value was determined.

Turbidity
Turbidity was monitored in a 1 cm quartz microcuvette using a Cary 50 UV-Vis
spectrophotometer (Agilent Technologies). At the given time points, 70 µL of undiluted
sample was placed into the cuvette and absorbance was measured at 400 nm using the
'Simple Read' program provided by the manufacturer in triplicates with 30 s delays.

Kinetics
The initial, or zero-hour, kinetics of an Aβ42 aggregation reaction were obtained in a
similar fashion to the aggregation reactions already described. For kinetics, however, the
reaction was prepared with all components except for the freshly purified Aβ42
monomer. For fluorescence, the fluorescence spectrophotometer was set as above, except
with a 15 min collection time. Immediately before measurement, the Aβ42 monomer was
mixed with the sample, and 5 µL of sample was combined with 70 µL of ThT in the
quartz cuvette. The sample was quickly mixed and inserted into the spectrophotometer
for data collection. For UV kinetics, the same sample preparation technique was used,
and absorbance measurements were taken on the Cary 50 UV-Vis spectrophotometer
using the 'Kinetics' program provided by the manufacturer.
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Size exclusion chromatography
Quantitative estimates of aggregation reaction were obtained using a Superdex-75
HR 10/30 size exclusion column (GE Life Sciences) on an AKTA FPLC system.
Aliquots of sample from the aggregation reactions were centrifuged and the supernatant
(100 µL) was loaded onto the SEC column. The samples were then subjected to
fractionation in 20 mM Tris-HCl, pH 8.0 at a constant flow rate of 0.5 mL/min and the
elution was monitored at the wavelength of 215 nm.

Polyacrylamide gel electrophoreses (PAGE) and immunoblotting
Samples were dissolved in loading buffer (1x Laemmli buffer) containing 1%
SDS, applied without heating to 4-12% NuPage gels (Invitrogen) containing bis-Tris, and
resolved in 2-(N-morpholino)ethanesulfonic acid (MES) running buffer with 0.1% SDS.
Dye-linked MW markers (Blue Plus2 Prestained Standards, Invitrogen) were run in
parallel for calibration. Gels were electroblotted onto 0.45 µm immobilon nitrocellulose
membranes (BioTraceTM NT, Life Sciences Inc). Blots were boiled in a microwave oven
in PBS for 2 min and were blocked overnight with 1X PBS containing 5% nonfat dry
milk and 0.1% tween-20 before probing (1-2 h) with 1:1000-1:2500 dilutions of Ab9
monoclonal antibody, which detects amino acid residues of Aβ (1-16). Blots were then
incubated with anti-mouse horseradish peroxide (HRP) conjugate and developed with
ECL reagent (Thermo Scientific).
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Circular dichroism (CD)
CD spectra were obtained in the far UV region with a Jasco J-815 spectropolarimeter
(Jasco Inc, Easton, MD). Aliquots of samples containing Aβ42 (25 µM) were placed in a
0.1 cm path-length quartz cuvette (Hellma) and were monitored in continuous scan mode
(260-190 nm). The acquisition parameters were 50 nm/min with 8 s response time, 1 nm
bandwidth and 0.1 nm data pitch, and data sets were averaged over three scans. All data
were collected in duplicate. Spectra of appropriate blanks were subtracted from the data
sets as indicated. The corrected, averaged spectra were smoothed using the ‘meansmovement’ algorithm with a convolution width of 25 using the Jasco spectra analysis
program.

Fluorescence anisotropy

Binding experiments were carried out by fluorescence anisotropy experiments using
an F19W-Aβ42 mutant. The excitation and emission wavelengths were fixed at 280 and
352 nm respectively with a spectral bandwidth of 30 nm (10 nm Ex and 20 nm, Em). The
ADL program on spectrometer was used and the G-factor was calculated for each
titration using Aβ42 F19W as the fluorophore. Each titration point was measured in
quadruplets after a brief equilibration time of 1 min, and the data points were averaged.
The data was converted to anisotropy (r) values using the 'Advanced Read' program
provided by the manufacturer. The data were fit into the following non-cooperative single
site binding equation using Origin 7.0 (Eq 2), where r0 and rs are anisotropy values in the
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absence and saturated levels of the ligand (BA), respectively, while Lt and Pt are the
respective total ligand and Aβ42 concentrations.

Results
AA, AS, and UM fail to inhibit Aβ42 fibrilization
Using ThT fluorescence as described above, we investigated the effect of asiatic
acid, asiaticoside, umbelliferone, and scopoletin on Aβ42 fibril formation. ThT is an
extrinsic dye that is known to show fluorescent properties upon binding to amyloid
aggregates29 and hence, it is used as an indicator to monitor Aβ fibril formation or
aggregation.
Figure 1A shows an aggregation profile of each compound incubated at a fourfold
molar excess to Aβ42. Although datasets from replicate incubations could not be
averaged due to the slight variation in purity of Aβ42 monomer, the chosen dataset is
typical of all aggregation profiles obtained. All compounds were dissolved in DMSO,
except for AS, which was soluble at 300 µM in water. Appropriate controls were
included for each solvent. We incubated 25 µM Aβ42 with 100 µM BA, AA, AS, or UM
in 20 mM TRIS, pH 8.0. Appropriate controls were also generated, with the same
percentage of DMSO (5%) included in the DMSO control as was present in the final
incubations of BA, AA, and UM. The aqueous control simply contained 25 µM Aβ42 and
20 mM TRIS at pH 8.0. Betulinic acid (▲) displayed an instantaneous increase in
fluorescence, which was sustained throughout the incubation period. Asiatic acid (Δ) and
the DMSO control (●) displayed a very similar aggregation profile, reaching a similar
maximum level of fluorescence with lag times of approximately 24 h. Earlier incubations
had shown umbelliferone to similarly diverge very little from the DMSO control (data
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not shown). Asiaticoside (□) displayed no major divergence from the aqueous control (■)
in either lag time or maximum fluorescence in this particular incubation, but in other
replications it seemed to cause slight inhibition of fibril formation (data not shown).
In order to further investigate the effect of these compounds on aggregation of
Aβ42, we incubated them at sixfold excess with E22G-Aβ42 mutant, in which the
glutamate residue at position 22 was replaced with glycine. E22G-Aβ42 typically
aggregates faster than wild type, and investigating the interaction of compounds with Aβ
mutants can help to determine which portions of the Aβ peptide are involved in the
interaction. Figure 1B shows that BA (○) again caused an increase in fluorescence with
no noticeable lag time, which remained high throughout the incubation. UM (▲) and AA
(□) had very similar fluorescence to the DMSO control (●) for the duration of the
experiment, and AS (Δ) again displayed very little divergence from the aqueous control
(■).
Since AS and BA were the only compounds to show any divergence from their
controls, we incubated them at a tenfold molar excess to Aβ42 in an attempt to make their
effect more apparent. 25 µM Aβ42 was incubated with 250 µM BA or AS in the same
conditions as previously described, with appropriate controls. Figure 1B shows that
betulinic acid (○) caused an even greater increase in total fluorescence with no noticeable
lag time, compared to the DMSO control (●). On the other hand, asiaticoside (Δ) did not
display any inhibitory effect compared to the aqueous control (■) at tenfold excess,
suggesting that the slight inhibition seen earlier was an experimental aberration.
However, the effect of BA was increased with increasing dosage, a phenomenon which
we chose to further investigate and characterize.
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BA rapidly augments Aβ42 fibril
formation

in

a

concentration

dependent manner
We explored the effects of
BA on Aβ42 aggregation by ThT

Figure 2. ThT Aggregation Profiles. ThT fluorescence
over time for incubations of A) fourfold molar excess of
BA (▲), AA (Δ), and AS (□) incubated with Aβ42, along
with DMSO control (●) and TRIS control (■); B) sixfold
molar excess of BA (○), UM (▲), AA (□), and AS (Δ)
incubated with E22G-Aβ42, along with DMSO control (●)
and TRIS control (■); and C) tenfold molar excess of BA
(○) and AS (Δ), along with DMSO control (●) and TRIS
control (■).

fluorescence and turbidity assays.
Since BA shows poor solubility in
aqueous buffers, we performed our
experiments
solvents:

in

two

dimethyl

different
sulphoxide

(DMSO) and ethanol (EtOH). As
described in a subsequent section,
we used EtOH as a solvent to
facilitate circular dichroism (CD)
measurements, as DMSO is not well
tolerated in CD. It was therefore
essential to monitor aggregation in
both solvents to ensure that the
interaction between betulinic acid
and Aβ42 was maintained.
We incubated 25 µM of
freshly

purified,

seed-free

monomeric Aβ42 with increasing

Figure 3. ThT Aggregation Profiles. ThT fluorescence
over time for incubations of A) fourfold molar excess of
BA (▲), AA (Δ), and AS (□) incubated with Aβ42, along
with DMSO control (●) and TRIS control (■); B) sixfold
molar excess of BA (○), UM (▲), AA (□), and AS (Δ)
incubated with E22G-Aβ42, along with DMSO control (●)
and TRIS control (■); and C) tenfold molar excess of BA
(○) and AS (Δ), along with DMSO control (●) and TRIS
control (■).
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concentrations of BA (from sub-stoichiometric ratio to four-fold excess) at 37 °C. Since
the stock solutions (1 mM) of BA were prepared in 100% DMSO or EtOH, incubations
of varying Aβ:BA stoichiometry resulted in different final concentrations of DMSO or
EtOH in the sample. A ratio of 1:4 Aβ42:BA contained 5%, 1:2 contained 2.5%, 1:1 had
1.25% while 1:0.5 contained 0.625% of DMSO or EtOH. Therefore, appropriate Aβ42
samples in similar solvents but in the absence of BA were used as controls (Figure 3B
and 3D). Aliquots of the incubated samples at the given time points were subjected to
fluorescence measurement upon addition of ThT buffer as shown in Figure 3A and 3C for
DMSO and EtOH, respectively. The data were fit using a sigmoidal equation (Eq. 1 in
Materials and Methods) to obtain lag-time information. Incubation in DMSO showed an
increase in Aβ42 aggregation rate as observed by both the increase in the fluorescence
intensity and the decrease in lag times as compared to the controls. The difference plots
shown in Figure 3E show the dose-response effect in which 1:4 ratio (□) had the highest
rate of aggregation, followed by 1:2 (▲), 1:1 (○) and 1:0.5 (■). The four-fold excess of
BA seemed to show immediate and sharp increase in ThT fluorescence intensity with no
noticeable lag-time (□ in Figure 3A and E). Even a sub-stochiometric ratio of 1:0.5 of
Aβ42:BA (■ in Figure 3E) resulted in augmentation of the aggregation rate as indicated
by the fluorescence increase after ~50 h of incubation. Similarly, incubations in EtOH
also resulted in augmented Aβ42 aggregation rates with lag times similar to those
observed with DMSO (Figure 3C). However, control incubations in EtOH but in the
absence of BA also resulted in increase in Aβ42 aggregation rates. Nevertheless, the
difference plots of the incubations in EtOH shows that there is a net increase in the
aggregation rates that is prominent with 1:4 stoichiometry (Figure 3F). It is noteworthy
that the incubation at a 1:4 molar ratio showed a rapid increase in ThT fluorescence in
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both solvents within the first 24 h (Figures 3E and F). Reproducible results were obtained
multiple times for both solvents. However, due to the slight variation in Aβ monomer
purity, the lag-times varied, making it difficult to average the data sets. Nevertheless,
overall reaction profiles remained identical to the one shown in Figure 2.
Since we observed maximal effect (in ThT measurements) with a fourfold molar
excess of BA, we explored only the sample of 25 µM Aβ42 incubated with 100 µM BA
in DMSO at 37 °C for the turbidity assay, since its primary purpose was to confirm the
validity of ThT measurements. We monitored aggregation by measuring the absorbance
at 400 nm in a UV-Vis spectrophotometer as previously described30. Aβ42 incubated
with BA showed a rapid increase in turbidity within 24 h of incubation and continued to
remain high, consistent with the ThT experiments (○; Figure 4A). The control Aβ42
sample in the absence of BA also displayed a similar trend; however, the absorbance
intensity was far lower (●; Figure 4A). The difference curve showed a rapid increase
during the initial 24 h that remained fairly stable for the remainder of the incubation
period (▲; Figure 4A). The difference curve was again similar to that for the ThT
fluorescence experiment (Figure 3A).
With 1:4 stoichiometric incubations we observed a sharp and apparently
instantaneous increase in both fluorescence and absorbance levels (Figures 3A and 4A,
respectively), and we wanted to ensure it was not an experimental aberration. Therefore,
we monitored the aggregation process immediately upon coincubation of BA and Aβ42.
As shown in Figure 4B, both ThT fluorescence and absorbance showed a rapid kinetic
process with similar exponential growth rates, suggesting a rapid and considerable
increase in aggregation rate induced by BA.
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Figure 3. Dose-dependent augmentation of Aβ42 aggregation by BA.
Aggregation was measured via ThT fluorescence over time. Incubations
comprised of 25 µM Aβ42 in 20 mM Tris, pH 8.0 at 37 ºC with increasing
amounts of BA dissolved in DMSO; A) 12.5 µM (■), 25 µM (○), 50 µM (▲),
100 µM (□). B) Controls containing DMSO concentrations corresponding to
12.5 µM, 25 µM, 50 µM, and 100 µM BA incubations respectively shown in A:
0.625% (▲), 1.25% (○), 2.5% (□), and 5% (■). C) Incubations comprising
buffered 25 µM Aβ42 with increasing amounts of BA dissolved in EtOH; 12.5
µM (■), 25 µM (○), 50 µM (▲), and 100 µM (□). D) Controls containing
varying EtOH concentrations; 0.625% (■), 1.25% (○), 2.5% (▲), and 5% (□).
E) Difference plot of BA dissolved in DMSO (A) and DMSO controls (B). The
control fluorescence at each time point was subtracted from the fluorescence of
the BA samples to generate the plot, which shows the molar stoichiometric
incubations, 1:0.5 (■), 1:1 (○), 1:2 (▲), and 1:4 (□). F) Similar difference plot
of BA dissolved in EtOH (C) and EtOH controls (D), which shows the molar
stoichiometric incubations, 1:0.5 (■), 1:1 (○), 1:2 (▲), and 1:4 (□). The Aβ:BA
stoichiometry is indicated by dotted arrows in E and F.
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Figure 4. Other assays also suggest rapid Aβ fibrillation induced by BA. A)
Turbidity assay was performed by measuring the absorbance at 400 nm for
buffered 25 µM Aβ42 in 5% DMSO at 37 ºC in the presence of 100 µM BA (○)
or in the absence of BA (●). The difference plot is also shown (▲). B)
Kinetics of the incubations in (A) was monitored immediately after incubation
ThT fluorescence (grey line) or absorbance at 400 nm (black line). C) The
samples in (A) were subjected to fractionation via SEC after 24 h of incubation.
The samples were subjected to centrifugation at 19000g for 15 minutes and the
supernatants were loaded on to the Sperdex-75 column. The sample containing
BA is shown as black line whereas the control sample in the absence of BA is
shown as a dotted line The monomers eluted at fractions 22-26, while the
aggregate peak near the void volume (Vo) between 15 and 17 (inset). D)
Sedimentation assay was performed by taking an aliquot of the co-incubation of
Aβ42 with four-fold molar excess of BA was measured for ThT fluorescence
after 24 h (T). In parallel, another aliquot of the same reaction was subjected to
centrifugation at 19000g for 15 min.
The supernatant thus obtained was
measured via ThT fluorescence (S). Three such data sets were averaged.

Sedimentation and SEC assays also indicate rapid Aβ42 fibrilization in the presence of
BA.
In order to quantify the proportion of monomeric Aβ42 being converted to
insoluble fibrils, we monitored the aggregation process by using sedimentation and size
exclusion chromatography (SEC). We monitored the depletion of monomers when Aβ42
was incubated with BA in comparison to a control in the absence of BA using a
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Superdex-75 SEC column. Since we observed the maximum difference between
experimental and control samples after 24 h of incubation with a fourfold molar excess of
BA (Figure 3A and 4A), we decided to fractionate a sample containing 25 µM Aβ42 and
100 µM BA, as well as a 25 µM Aβ control, after 24 h incubation at 37 °C. First, we
centrifuged each sample at 19,000g for 15 minutes in order to sediment any pre-formed
insoluble fibrils that may have interfered with the SEC column. The supernatant was then
loaded on to the column for fractionation. The Aβ42 control incubation in the absence of
BA showed a distribution containing mainly the monomeric peak, which eluted in
fractions, 24 and 25 along with a minor amount of aggregated material eluting near the
void volume (V0) of the column (Figure 4C; dotted line). The Aβ42 sample in the
presence of BA showed a similar fractionation profile (Figure 4C; solid line); however,
the amount of monomer was far less than that of the control sample. This suggests that
the presence of BA promotes rapid fibril formation, leading to a concomitantly decrease
in the amount of monomers. Furthermore, it is interesting to note that the sample with BA
also contained some aggregates that eluted near the void volume (Figure 4C; inset).
However, the amount of the aggregated peak was less than that observed for the control
sample. Since these aggregates were non-fibrillar, soluble intermediates (as the fibrils had
been spun out prior to fractionation), this observation suggests that BA promotes
insoluble fibril formation at the expense of soluble aggregates. Finally, in order to ensure
that the aggregates formed in the presence of BA are indeed fibrils, we performed a
sedimentation assay. After 24 hours of incubating 25 µM Aβ42 with BA in fourfold
excess, we measured ThT fluorescence as previously described. We then spun the sample
at 19,000g for 15 minutes and measured the ThT fluorescence of the supernatant. As
shown in Figure 4D (grey bars), only ~30 % of fluorescence was observed after
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sedimentation, suggesting a large amount fibril formation within 24 h of incubation.
Furthermore, mass spectrometry analysis of the supernatant and pellet from the coincubated sample after multiple spins, rinsing the pellet each time, revealed that all BA
was associated with the fibrils and none was observed in the supernatant (data not
shown), suggesting that BA is incorporated or tightly complexed with the fibrillar
structure. Collectively, these data suggest that BA was able to rapidly promote the
formation of insoluble Aβ42 fibrils from monomeric species and bypass soluble
oligomeric intermediates in doing so.

Oligomers are absent in co-incubations of Aβ42 and BA
We also subjected the
samples incubated in Figures
3A and B to electrophoresis
and immunoblotting to see
whether

the

results

complemented the experiments
described above. Shown in
Figure 5 are immunoblots of
samples

of

Aβ42

with

a

fourfold excess of BA prepared
in the same fashion as those in
Figure

3A,

along

with

appropriate controls. Clearly,

Figure 5. Aβ42 aggregation in the presence of BA monitored
by immunoblots. Samples containing 25 µM Aβ42 were
incubated alone (control) or with 100 µM BA (+BA) at 37 ºC. The
aliquots of the sample was taken at the indicated time points and
were run on a SDS-PAGE gel followed by western blotting and
immunodetection. The lanes T & S represent total and supernatant
(after spinning the sample at 19000g for 20 min to remove fibrils)
respectively, after 0, 24 & 48 h of incubation.

the control sample in the absence of BA showed no high molecular weight bands for 24 h
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(Figure 5A: 24h). After 48 h, aggregate bands of ~100 kDa were apparent, along with
some high molecular weight bands that failed to enter the gel consistent with fibrils (F)
(Figure 5A: 48 h). In contrast, samples with BA showed a fibril band (F) within 24 h of
incubation. More importantly, the supernatant after centrifuging the sample at 19000g for
15 minutes failed to show the high molecular band (Figure 5B; 24 h, S), confirming that
these bands correspond to fibrils. A similar pattern was observed after 48 h of incubation
(Figure 5B; 48 h). Although the control sample showed similar bands at 48 h, they were
also present in the supernatant, suggesting the bands may correspond to non-fibrillar,
‘non-pelletable’ forms of aggregates. These results confirm that BA is able to promote
insoluble fibril formation from Aβ42 monomer within 24 hours and also suggest that this
occurs in a manner that bypasses the formation of soluble, pre-fibrillar aggregates.
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BA induces rapid changes in Aβ42 secondary structure.

Figure 6. Secondary structure changes in Aβ42 upon
incubation with BA. Co-incubation reactions containing fourfold molar excess of BA in EtOH similar to those shown in Figure
2C were monitored using far-UV CD (solid lines) along with
control in the absence of BA (dashed lines) at the indicated time
points (A-D). E) The difference plot obtained by subtracting the
molar ellipticity values at 216 nm of the control sample from the
sample containing BA (■), which was overlayed with the
difference plot shown in Figure 2F for 1:4 stoichiometry (○)

The secondary structure changes during the incubation of Aβ42 with BA were
monitored by far-UV CD spectroscopy. Since DMSO solvent is not compatible with CD
measurements, Aβ42 was incubated in a fourfold excess of BA in 5% EtOH along with
an appropriate control as in Figure 3C and 3D. Both the control sample and the one coincubated with BA displayed a random coil conformation immediately (10 min) after
incubation (Figure 6A). However, the molar ellipticity at 216 nm was slightly more
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negative for the sample with BA, suggesting a conformational change toward β-sheet.
After 24 h of incubation, the sample containing BA clearly displayed a spectrum with
negative minimum at 216 nm and positive maximum at ~198 nm, indicating a β-sheet
conformation characteristic of Aβ fibrils (Figure 6B). By contrast, the control sample
displayed predominantly a random coil structure (Figure 6B). After 48 h, both the control
as well as the sample containing BA showed β-sheet conformation and remained in the
same conformation for more than 120 h (Figure 6C and 6D). A comparison of the
difference spectra obtained from ThT and CD experiments indicated identical changes
(Figure 6E). It is clear that the maximal difference of BA compared to controls was
observed during the initial 24 h of incubation, which complements the results obtained
from ThT, turbidity, SEC, sedimentation assays, and immunoblots.

BA binds to monomeric Aβ42 with sub-micromolar binding affinity.
Finally, we wanted to explore the binding interaction between Aβ42 and BA. In
order to do so, we used an Aβ42 F19W mutant peptide in which the phenylalanine at the
19th position was substituted with a tryptophan residue to facilitate fluorescence
anisotropy measurements. Although the wild-type Aβ contains a tyrosine (Tyr) residue at
the 10th position, Tyr is not a good fluorophore and the emission intensities were
prohibitively low for anisotropy experiments. Aβ40 F19W mutant has been previously
observed to exhibit no significant difference in aggregation and fibril formation
compared to wild type Aβ4031. To ensure that there was also no significant difference
between wild-type Aβ42 and the mutant, we performed ThT experiments both in the
presence and in the absence of BA (data not shown). These experiments did not show
significant divergence from aggregation profile of wild-type Aβ42. Upon titrating BA to
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a freshly purified monomeric
Aβ42

F19W

sample,

we

observed a constant increase in
tryptophan
reflecting

anisotropy
binding

(r)

interaction

between the two species(Figure
7; ●). Fitting the data using the
non-interacting one-site binding
equation (Equation 2) yielded an
apparent dissociation constant
(KDapp = 11.02 ± 2.01 µM).
Since

BA

induces

rapid

aggregation, especially at high
molar ratios, the FA experiments

Figure 7. Binding affinity between Aβ42 and BA measured
by fluorescence anisotropy. The specific mutant, F19WAβ42
was used as a probe to measure tryptophan anisotropy (r).
Aliquots of mixtures containing 5 µM Aβ42 and 50 µM BA in
2.5 % DMSO was titrated on a solution containing 5 µM Aβ42
in a similar solvent (●). The anisotropy was measured in
quadruplets for each titration points that were averaged. As a
negative control similar experiment was performed using
glycylglycine instead of BA (○). Three independent data sets
were averaged and fit with a model for a single site binding (Eq
2).

may not reflect the binding interactions between BA and monomeric Aβ exclusively. For
this reason, we refer to the binding affinity as 'apparent,' KDapp. A dipeptide, glycylglycine (GG) was used as a negative control and did not show any appreciable binding
isotherm (Figure 7; ○).
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Discussion
The design of therapeutics for any disease is a process that faces many challenges.
Synthetic, rationally designed drugs, while having excellent potential for specificity,
require the development of an efficient synthetic pathway and extensive testing for
toxicity. As the world saw with Thalidomide in the 1970's, even a simple change in
stereochemistry can lead to vastly altered biological effects. Natural products offer an
attractive alternative to synthetic drugs. They are generally produced in abundant
quantities in plants or herbs, the efficacy of their synthesis has been streamlined by
millions of years of evolution, and they are often already components of the human diet.
In addition, many of these products are already in use in ancient forms of traditional
medicine, such as the Ayurvedic system of India. It is entirely likely thorough screening
of the natural products used in traditional herbal remedies and concoctions will yield a
plethora of active compounds and combinations of compounds that can provide
significant benefits to human health.
The compounds tested here are all components of such concoctions, and it is
important to note that even if a compound does not directly alter the aggregation of Aβ, it
still has the potential to be beneficial in the treatment of AD. For asiatic acid and
asiatoside, this is almost certainly the case. Although our investigations yielded no direct
interaction between the Aβ42 peptide and either molecule, they have both been shown by
previous researchers to be beneficial in this regard19-24. Umbelliferone has not been
extensively researched in connection to AD, and again, although we showed no direct
interaction between it and Aβ42 in vitro aggregation, they may still provide some in vivo
benefit that our assays did not detect. Betulinic acid proved not to be an aggregation
inhibitor, which is the type of compound we initially sought, but it may still mitigate the
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AD pathology in some way, especially considering its ability to promote the formation of
fibrils at the expense of neurotoxic oligomers, discussed in greater detail below.
The development of Aβ aggregation inhibitors in particular involves several
challenges; a) the difficulty in controlling the stage of inhibition during the aggregation
process, and b) the possible increase in the soluble oligomer concentrations upon
inhibition of fibril formation may be detrimental, as smaller soluble oligomers are known
to more toxic than fibrils. Therefore, an ideal way of developing therapeutically viable
aggregation inhibitors would be to trap Aβ at the monomeric level, since monomers are
not toxic. However, it is difficult to design molecules against intrinsically disordered,
monomeric Aβ due to its high conformational flexibility and lack of structurally welldefined recognition motifs. Considering such difficulties, it is not surprising that few
aggregation inhibitors have successfully made it though the clinical trials.
In this context, it is perhaps worthwhile to consider designing molecules that can
prevent the formation of neurotoxic oligomers by circumventing these pathogenic
species. The results reported here suggest BA is precisely able to perform such a task and
showcase the potential use of BA as a therapeutic agent against AD. The mechanism of
augmentation of aggregation by BA is not entirely a new observation as previously,
compounds such as methylene blue and ellagic acid have also been reported to promote
rapid Aβ42 fibril formation and inhibit neurotoxicity30,32.

29

NATURAL PRODUCTS AND Aβ

However, the rapid fibrillation induced by BA as reported here, which comes at
the expense of toxic soluble oligomers, seems to be exclusive to the fibril formation ‘onpathway’. As it is increasingly becoming evident that many neurotoxic oligomers can be
formed outside the obligatory fibril formation pathway, we explored whether BA is able
to circumvent such oligomer formation also. BA failed to induce the formation of fibrils
and concomitantly inhibit the formation of 12-18mer oligomers (Figure 8; lanes 1 and 2),
which were reported to be formed along an alternate pathway of aggregation called ‘offpathway’16. In addition, BA
failed to convert isolated 1218mers to fibrils rapidly as
observed

with

monomers

(Figure 8), suggesting that BA
is unable to interact with
oligomers that are not formed
along the fibril formation ‘onpathway’. These suggest that;
a) BA is extremely potent in
promoting

rapid

formation

along

pathway’,

and

fibril
the

b)

BA

‘onis

incapable of interacting with
aggregates

along

alternate

pathways of aggregation.

Figure 8. Effect of BA on ‘off-pathway’ oligomers. Lanes 1 &
2 show 25 µM Aβ42 containing 5 % DMSO incubated with 5mM
lauric acid alone and in the presence of 100 µM BA respectively.
In parallel, the SEC isolated oligomers were also incubated alone
and with 100 µM BA at 37 ºC. The aliquots of the sample was
taken at the indicated time points and were electrophoresed and
immunoblotted. The lanes T & S represent total and supernatant (
after spinning the sample at 19000g for 20 min to remove fibrils)
respectively, after 0 & 24 h. The double arrows indicate 12-18mer
oligomers of Aβ42.
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Pharmacologically, the properties of BA are well known, and the compound is
being administered for a variety of pathologies. Historically, extracts of Bracopa
monniera have been used in Ayurvedic medicines for the treatment of CNS disorders and
impaired mental function27,33. They are also thought to improve higher order cognitive
processes that are critically dependent on the input of information from our environment
such as learning and memory33. In addition, white birch bark, Betula alba, which contains
BA, has been extensively used by native Americans to treat intestinal disorders. BA is
also widely used in modern medicine34-39,43. BA has shown great promise as a potential
therapeutic for a variety of cancer types, and, furthermore, BA is also known to inhibit
HIV viral replication36,40. Due to the distinct pharmacological advantages of BA as a
therapeutic agent along with its unique property of promoting Aβ fibril formation and
especially bypassing toxic oligomers along the ‘on-pathway’ fibril formation as reported
here, BA is an excellent therapeutic candidate for AD. Therefore, understanding the
effects of BA in in vivo systems such as cell culture and animal models is imperative for
drug development. Our future experiments are focused on addressing these aspects and
will be published later.
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